Similar meta-analyses were also performed to determine the relationship between FGF21 and CV death in patients with CAD, but no significant associations were found, irrespective of the main outcome, including three studies (RR: 1.04, 95% CI: 0.93–1.17, P > 0.05, I2 = 80%, random-effect model) or the sensitivity analysis including two studies reporting RR (RR: 1.01, 95% CI: 0.99–1.02, P > 0.05, I2 = 0%, fixed-effect model). Here, FGF21 is linked to coronary artery disorder.